Stock PULM PULMATRIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Pulmatrix, Inc.

Equities

PULM

US74584P3010

Market Closed - Nasdaq
Other stock markets
 21:30:00 03/05/2024 BST 		5-day change 1st Jan Change
1.96 USD -3.44% Intraday chart for Pulmatrix, Inc. -3.92% +5.38%
03-28 Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-13 Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer
Pulmatrix Explores Strategic Alternatives
Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Sector Update: Health Care Stocks Easing Late Tuesday
Sector Update: Health Care Stocks Lower Tuesday Afternoon
Pulmatrix Seeks FDA Approval to Launch Phase 2 Trial of Investigational Drug for Acute Migraine Treatment; Shares Rise
Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Pulmatrix Doses First Patient in Phase 2b Asthma Trial
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis in Subjects with Asthma
Pulmatrix Reports Top-Line Results From Acute Migraine Treatment
Pulmatrix, Inc. Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine, for Acute Migraine
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Pulmatrix Completes Patient Dosing for Phase 1 Study of Acute Migraine Drug Candidate
Pulmatrix, Inc. Announces Patient Dosing Completed for Its Novel Inhaled Therapy PUR3100 for Acute Migraine
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PULM Stock
  4. News Pulmatrix, Inc.
  5. Other languages